Back to top
more

Summit Therapeutics (SMMT)

(Real Time Quote from BATS)

$27.75 USD

27.75
965,543

-0.77 (-2.70%)

Updated Aug 7, 2025 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks News

Zacks Equity Research

Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session

Shares of Apricus Biosciences (APRI) rose about 9% yesterday.

    Zacks Equity Research

    Sarepta's Golodirsen Positive in DMD Study, Shares Soar

    Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

      Zacks Equity Research

      Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer

      Jazz Pharmaceuticals (JAZZ) announces private offering of exchangeable senior notes to qualified institutional buyers to raise proceeds and repay debt.

        Zacks Equity Research

        Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised

        Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.

          Zacks Equity Research

          Jazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact

          Jazz Pharma's (JAZZ) earnings and revenues miss estimates. However, the top line rises year over year owing to higher sales of the company's marketed drug, Xyrem.

            Zacks Equity Research

            Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress

            Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.

              Zacks Equity Research

              Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss

              Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.

                Zacks Equity Research

                Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

                Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.

                  Zacks Equity Research

                  Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View

                  Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.

                    Zacks Equity Research

                    Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered

                    Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.

                      Zacks Equity Research

                      Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected

                      Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.

                        Zacks Equity Research

                        Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

                        Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.

                          Zacks Equity Research

                          Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

                          Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

                            Zacks Equity Research

                            Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

                            Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

                              Zacks Equity Research

                              Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy

                              Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy

                                Zacks Equity Research

                                Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View

                                Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.

                                  Zacks Equity Research

                                  Can Summit Therapeutics (SMMT) Run Higher on Strong Earnings Estimate Revisions?

                                  Summit Therapeutics (SMMT) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                                    Zacks Equity Research

                                    Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

                                    We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

                                      Zacks Equity Research

                                      Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop

                                      Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.

                                        Kinjel Shah headshot

                                        Glaxo Files for Label Expansion of Influenza Vaccine in US

                                        GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.

                                          Zacks Equity Research

                                          Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

                                          We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

                                            Zacks Equity Research

                                            J&J Presents Positive Phase III Data on Psoriasis Candidate

                                            Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

                                              Zacks Equity Research

                                              Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat

                                              Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.

                                                Zacks Equity Research

                                                Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data

                                                Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.

                                                  Zacks Equity Research

                                                  BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

                                                  BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.